Biomarin Pharmaceutical Inc (BMRN)
65.60
-1.06
(-1.59%)
USD |
NASDAQ |
Nov 14, 16:00
65.58
-0.02
(-0.03%)
After-Hours: 20:00
Biomarin Pharmaceutical Free Cash Flow (Quarterly): 200.30M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 200.30M |
| June 30, 2024 | 96.92M |
| March 31, 2024 | 12.87M |
| December 31, 2023 | -9.213M |
| September 30, 2023 | 112.23M |
| June 30, 2023 | 47.33M |
| March 31, 2023 | -98.70M |
| December 31, 2022 | -29.57M |
| September 30, 2022 | 121.85M |
| June 30, 2022 | 28.19M |
| March 31, 2022 | -76.11M |
| December 31, 2021 | -33.18M |
| September 30, 2021 | 76.70M |
| June 30, 2021 | 56.53M |
| March 31, 2021 | 85.26M |
| December 31, 2020 | -53.25M |
| September 30, 2020 | 66.05M |
| June 30, 2020 | -5.748M |
| March 31, 2020 | -59.21M |
| December 31, 2019 | -3.499M |
| September 30, 2019 | 34.72M |
| June 30, 2019 | -61.03M |
| March 31, 2019 | -85.33M |
| December 31, 2018 | 7.295M |
| September 30, 2018 | -2.659M |
| Date | Value |
|---|---|
| June 30, 2018 | -56.38M |
| March 31, 2018 | -72.67M |
| December 31, 2017 | -25.28M |
| September 30, 2017 | -4.19M |
| June 30, 2017 | -28.98M |
| March 31, 2017 | -149.53M |
| December 31, 2016 | -51.78M |
| September 30, 2016 | -36.46M |
| June 30, 2016 | -71.31M |
| March 31, 2016 | -216.66M |
| December 31, 2015 | -169.66M |
| September 30, 2015 | -47.41M |
| June 30, 2015 | -48.45M |
| March 31, 2015 | -181.64M |
| December 31, 2014 | -51.67M |
| September 30, 2014 | -33.73M |
| June 30, 2014 | -51.98M |
| March 31, 2014 | -50.10M |
| December 31, 2013 | -38.75M |
| September 30, 2013 | -22.69M |
| June 30, 2013 | -17.23M |
| March 31, 2013 | -43.86M |
| December 31, 2012 | -1.909M |
| September 30, 2012 | -0.799M |
| June 30, 2012 | -10.90M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-98.70M
Minimum
Mar 2023
200.30M
Maximum
Sep 2024
26.79M
Average
20.53M
Median
Free Cash Flow (Quarterly) Benchmarks
| Merck & Co Inc | 8.508B |
| Bristol-Myers Squibb Co | 5.267B |
| Alnylam Pharmaceuticals Inc | 39.52M |
| Repligen Corp | 34.79M |
| Bioventus Inc | 10.25M |